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OBJECTIVES The purpose of this study was to determine the mechanistic basis for thrombin generation and
increased prothrombotic potential after the abrupt cessation of intravenous (IV) unfractionated
heparin among patients with acute coronary syndromes.
BACKGROUND A “rebound” increase in prothrombotic potential has been observed biochemically and
clinically after the abrupt cessation of unfractionated heparin (UFH) among patients with
acute coronary syndromes. Although the mechanism is unknown, tissue factor and the
extrinsic coagulation cascade, both operative in atherosclerotic vascular disease and arterial
thrombosis, are thought to be centrally involved.
METHODS In a single-center, pilot study, 30 patients with either unstable angina or non-ST segment
elevation myocardial infarction who had received a continuous IV infusion of UFH for 48 h
were randomly assigned to: 1) abrupt cessation, 2) IV weaning over 12 h or 3) subcutaneous
weaning over 12 h.
RESULTS Thrombin generation (prothrombin fragment 1.2) was evident within 1 h of UFH cessation,
increased progressively (by nearly two-fold) at 24 h (p 5 0.002) and correlated inversely with
tissue factor pathway inhibitor concentration (r 5 20.61). Thrombin generation was greatest
among patients randomized to abrupt cessation (1.6-fold increase at 24 h) and least in those
with IV weaning.
CONCLUSIONS Thrombin generation after the abrupt cessation of UFH may represent a drug-induced
impairment of physiologic vascular thromboresistance in response to locally generated tissue
factor. A dosing strategy of abbreviated IV weaning attenuates but does not prevent heparin
rebound among patients with acute coronary syndromes. (J Am Coll Cardiol 1999;34:
1020–7) © 1999 by the American College of Cardiology
Intravenous (IV) unfractionated heparin (UFH) is widely
used in the management of patients with acute coronary
syndromes, particularly those with unstable angina and
non-ST segment elevation myocardial infarction (MI)
(1–4) in whom atheromatous plaque disruption and intra-
coronary thrombosis commonly co-exist (5). Despite its
proven beneficial effects as an adjunct to treatment strategies
that commonly include aspirin, beta-adrenergic blocking
agents, nitrates and, more recently, platelet glycoprotein
IIb/IIIa antagonists, clinicians have documented and re-
main concerned about a resurgence of symptoms and a
clustering of thrombotic events shortly after the cessation of
UFH (6,7) and other thrombin antagonists (8–10).
Whether the observed clustering of thrombotic coronary
arterial events shortly after UFH cessation represents a
removal of suppression (of an underlying prothrombotic
environment that has remained quiescent during treatment)
(10,11) or true “rebound” was first investigated by Granger
et al. (12). Thirty-five patients with unstable angina or acute
MI who had received a continuous IV infusion of UFH for
at least 48 h were studied. Thrombin generation measured
in plasma increased transiently but significantly within 3 to
6 h of UFH cessation, supporting the hypothesis that a
“rebound” prothrombotic state develops rapidly in patients
with acute coronary syndromes when anticoagulant therapy
is discontinued abruptly.
The very important questions that remain unanswered,
however, are:
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1) What is the mechanistic basis for heightened thrombin
generation following UFH cessation? and
2) Is it possible to prevent or attenuate the response by
either gradual discontinuation (weaning) of heparin
therapy or by switching from IV to subcutaneous (SC)
heparin administration as suggested by the National
Heart, Lung, and Blood Institute (NHLBI)-sponsored
“Clinical Practice Guideline” for unstable angina (1)?
Because the extrinsic or tissue factor-mediated coagula-
tion pathway is considered to be the predominant means for
both physiologic hemostasis and pathologic arterial throm-
bosis (13,14), we were particularly interested in alterations
of physiologic protection (vascular thromboresistance) that
may occur during and after prolonged UFH administration.
METHODS
Patient population. Patients admitted to the University of
Massachusetts-Memorial Medical Center between July 1,
1997 and May 1, 1998 were evaluated for entry into a
single-center pilot study designed to investigate the bio-
chemical basis and potential attenuation of heparin re-
bound. Thirty patients who fulfilled the following criteria
were enrolled: 1) age . 18 years, 2) within 72 h of hospital
admission for either unstable angina at rest with ST-
segment deviation of at least 1 mm or non-ST segment
elevation MI (elevated creatine kinase with CK-MB (crea-
tine kinase MB isoenzyme) index .2.2) and 3) at least 48 h
of a continuous infusion of UFH. All patients received
aspirin at a dose of 160 to 325 mg daily. Patients receiving
fibrinolytic therapy within the previous 96 h were excluded
as were patients with refractory ischemia, moderate to severe
congestive heart failure, hemodynamic instability requiring
inotropic or intraaortic balloon counterpulsation support, an
infusion of UFH for more than 12 h before admission to the
coronary care unit and those who had undergone a percu-
taneous coronary intervention (PCI) within 72 h of screen-
ing. Patients with either a platelet count less than 90,000 per
mm3 (at any time) or a 30% or greater decline from baseline
during treatment were also excluded. The study was ap-
proved by the University of Massachusetts-Memorial Com-
mittee for the Protection of Human Subjects. Written
informed consent was obtained from each patient before
enrollment.
Study design. The overall use and duration of IV UFH
therapy was at the discretion of the treating physician. All
patients had their heparin titrated to a target activated
partial thromboplastin time (aPTT) between 55 and 80 s
according to a standardized and validated, weight-adjusted
dosing nomogram. All aPTT measurements were made
using a point-of-care instrument (Coaguchek Plus,
Boehringer-Mannheim Corporation, Indianapolis, Indiana).
When the treating physician believed that IV UFH was
no longer required (completion of therapy), randomization
(using sealed envelopes) of patients to one of three dose
modification strategies was performed: Group 1—the IV
UFH infusion was discontinued, Group 2—the IV UFH
infusion was reduced by 50% from the previous infusion rate
and discontinued 12 h later (IV wean) or Group 3—the IV
infusion was discontinued and UFH (12,500 U) was given
SC within the subsequent 4 h followed by a repeat dose
(12,500 U) 12 h later (SC wean). Staff nurses carrying out
the dosing changes were blinded to the study.
Blood sampling and processing. Baseline blood samples
were obtained 60 min before discontinuation of the IV
UFH infusion. Additional samples were obtained at 1, 4
and 24 h after heparin cessation. Blood samples were
collected for determination of heparin levels (anti-Xa),
aPTT, factor VII/VIIa, tissue factor pathway inhibitor
(TFPI) antigen (total), TFPI activity, protein C and pro-
thrombin fragment 1.2 (F1.2).
All blood samples were obtained by a single trained
phlebotomist through a fresh venipuncture site using a
21-gauge Vacutainer (Franklin Lakes, New Jersey) collec-
tion set. Sampling was not performed through existing
venous or arterial sheaths and special care was taken to
perform each phlebotomy in the contralateral arm to an
existing heparin infusion. Two tubes of blood were collected
at each time point: a 4.5 ml sodium citrate tube and a 5 ml
tube with lyophilized (EDTA) (4.5 mM), D-Phe-Pro-Arg
chloromethyl ketone (PPACK) (20 mM) and aprotinin
(150 KIU/ml). The samples were immediately placed on ice,
processed within 60 min of collection and stored at 220°C
to 270°C.
Laboratory assays. All assays were performed in the Lab-
oratory for Vascular Biology Research, University of Mas-
sachusetts Medical School. Test samples, standards and
reference samples were measured in duplicate.
Heparin levels were measured using anti-Xa concentra-
tion (Coatest, Chromogenix AB, Sweden). Activated partial
thromboplastin times (Biopool, Ventura, California) were
measured using standard methods and a Mag-X Coagula-
tion Analyzer (Organon Teknika, Durham, North Caro-
Abbreviations and Acronyms
ACC 5 American College of Cardiology
AHA 5 American Heart Association
ANOVA 5 analysis of variance
aPTT 5 activated partial thromboplastin time
CAD 5 coronary artery disease
ELISA 5 enzyme-linked immunosorbent assay
F1.2 5 prothrombin fragment 1.2
IV 5 intravenous
MI 5 myocardial infarction
NHLBI 5 National Heart, Lung, and Blood Institute
PCI 5 percutaneous coronary intervention
SC 5 subcutaneous or subcutaneously
TFPI 5 tissue factor pathway inhibitor
UFH 5 unfractionated heparin
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lina). Prothrombin activation fragment 1.2 was calculated
using a two-site, enzyme-linked immunoassay (Enzygnost
F1.2, Boerhinger Diagnostics Inc., Westwood, Massachu-
setts). Two murine monoclonal antibodies against human
factors VII and VIIa (American Diagnostica Inc., Green-
wich, Connecticut) were used to measure plasma factor VII
antigen concentration by enzyme-linked immunosorbent
assay (ELISA), while factor VIIa in the presence of recom-
binant soluble tissue factor was determined by plotting
factor VIIa levels against a corresponding clotting time
(Staclot VIIa-rTF, Diagnostica Stago, France).
Tissue factor pathway inhibitor antigen (total) was deter-
mined using an Imubind enzyme-linked immunosorbent
assay (American Diagnostica Inc., Greenwich, Connecti-
cut). Tissue factor pathway inhibitor activity was calculated
using the Actichrome TFPI activity assay (American Diag-
nostics, Inc.) in which TFPI exhibits an inhibitory effect on
the factor VIIa/tissue factor complex.
Statistical analysis. Analytical methods included simple
univariate statistics, correlations and analysis of variance
(ANOVA). Univariate analyses were performed on all
variables of interest to examine and describe the nature of
variability and to assess normality of the data. Heparin
concentration and hemostatic variables were analyzed with
repeated measure ANOVA for all patients and by group.
Changes over the 24 h study period were calculated using
the latest time point value minus the baseline value, and
percent change was computed by dividing this change value
by the baseline value. Pearson correlation coefficients were
calculated to assess the association between measures of the
change variables. Univariate and correlation analyses were
carried out using SAS (Cary, North Carolina), and repeated
measures ANOVA were performed using SPSS (Chicago,
Illinois).
RESULTS
Patient characteristics: overall study population. A total
of 30 patients was included in the pilot study. Approxi-
mately two-thirds were men with an average age of 63.8
years (range 28 to 95 years). A majority had an admitting
diagnosis of MI (60%), whereas 40% had unstable angina.
The duration of heparin treatment ranged from 48 to 62 h
(mean 52 h, range 48 to 62 h) with an average hourly
infusion rate of 1,178 U (range 600 to 2,000 U). Oral
beta-blockers, nitrates, calcium channel blockers, aspirin
and angiotensin converting enzyme inhibitors were admin-
istered to 63%, 80%, 33%, 100% and 33% of patients,
respectively.
Coagulation measurements. The mean heparin concen-
tration immediately before modification of the UFH infu-
sion was 0.45 U/ml (60.21 U/ml) with a corresponding
aPTT value of 56.6 s (629.7 s). Thrombin generation,
expressed as F1.2 concentration, increased from a baseline
value of 2.19 6 0.80 nM to a maximum of 3.59 6 1.03 nM
at 24 h (p 5 0.002). Although increased thrombin gener-
ation was evident within 1 h of modifying the heparin
infusion (2.25 6 0.9 nM), a more substantial increase was
observed at 4 h (2.47 6 0.8 nM, 15.3% increase from
baseline). Thrombin generation persisted beyond 4 h, with
an 81.5% overall increase from baseline appreciated at 24 h.
Comparison of heparin strategy groups. The baseline
characteristics and heparin dosing of patients in each of the
study groups are presented in Table 1. There were no
significant differences in any of the measured parameters.
Changes in hematologic variables over time for each of
the heparin strategy groups are shown in Tables 2–4.
Thrombin generation increased in all groups by 4 h and
peaked 24 h after modification of the UFH dose (Fig. 1).
The percentage increase above the baseline value was
greatest among patients randomized to abrupt discontinu-
ation in whom F1.2 rose by 20.2% at 4 h and 164% at 24 h
(p , 0.01). The observed changes were less striking, but still
significant, in patients randomized to the SC weaning
strategy (7.7% increase at 4 h, 57% increase at 24 h, p 5
0.006) and those having an IV UFH wean (20.5% increase
at 4 h, 44.5% increase at 24 h, p 5 0.02). There were no
statistically significant differences in F1.2 at any time point
between the heparin strategy groups.
Table 1. Baseline Characteristics and Heparin Dosing for the Study Groups
Group 1
Heparin
Discontinued
(n 5 10)
Group 2
Intravenous
Heparin
Wean (n 5 10)
Group 3
Subcutaneous
Heparin
Wean (n 5 10)
Age (mean) (yr) 60 66.2 65.2
Gender (% male) 60 60 80
Weight (kg) 79.1 81.9 75.6
Admitting diagnosis
MI 6 (60%) 6 (60%) 6 (60%)
Unstable angina 4 (40%) 4 (40%) 4 (40%)
Heparin dose (mean) 1175 U/h 1170 U/h 1190 U/h
Heparin dose per kg 14.9 U/kg/h 14.2 U/kg/h 15.7 U/kg/h
Duration of treatment (mean) 46.2 h 54 h 49 h
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Changes in TFPI and factor VIIa were also evident
during the study period and differed among the three
heparin strategy groups. By 4 h, TFPI (total) and TFPI
(activity) had declined, with the greatest proportional de-
creases being observed in patients having their UFH termi-
nated abruptly (44% and 23% reduction, respectively, p 5
0.03 for the change in TFPI [total]), compared with those
having IV (11% and 0.3% reduction, p 5 0.24) or SC (32%
and 10% reduction) weaning. Factor VIIa levels increased
more than two-fold in patients randomized to abrupt UFH
cessation (p 5 0.02) and to a lesser degree in patients having
IV (74% increase, p 5 0.01) or SC (35% increase, p 5 0.04)
weaning (Figs. 2 and 3).
By 24 h, TFPI (total) and TFPI (activity) were most
notably decreased among patients randomized to SC UFH
weaning (41% and 11% reduction, respectively).
Correlations. Thrombin generation at 4 h correlated di-
rectly with factor VII (r 5 0.22) and factor VIIa (r 5 0.17)
and inversely with TFPI (total) (r 5 20.61) and TFPI
(activity) (r 5 20.66). Changes in heparin concentration
correlated inversely with F1.2 (r 5 20.19) and directly with
TFPI (total) (r 5 20.29). Thrombin generation at 24 h
correlated inversely with heparin concentration (r 5
20.29), TFPI (total) (r 5 20.32) and TFPI (activity) (r 5
20.59). Tissue factor pathway inhibitor (total) (r 5 0.35)
and TFPI (activity) (r 5 0.35) correlated directly with the
change in heparin concentration from baseline to 24 h.
Clinical events. Recurrent angina prompting emergent
coronary angiography and PCI occurred in two patients
randomized to immediate UFH cessation. Both events were
within 12 h of stopping the heparin infusion. Clinical events
did not occur in patients randomized to either IV or SC
heparin weaning.
DISCUSSION
The early management of patients with unstable angina and
non-ST segment elevation MI commonly includes a strat-
egy of antithrombotic therapy with IV UFH. A resurgence
of symptoms following its abrupt cessation, however, has
concerned clinicians for over a decade and, in all likelihood,
compromises UFH’s overall treatment effect. In our pro-
spective, randomized pilot study, several new observations
were made. First, thrombin generation was evident within
1 h of UFH cessation and increased steadily over the
subsequent 24 h. Second, thrombin generation correlated
inversely with heparin and TFPI concentrations, suggesting
that tissue factor-mediated coagulation or impaired vascular
thromboresistance are contributing factors. Third, the rap-
idly developing prothrombotic environment that follows
UFH cessation is modifiable but not fully prevented by a
strategy of IV weaning. Finally, SC weaning delays, but
does not prevent, thrombin generation.
Thrombin generation in acute coronary syndromes. In
vivo, thrombin serves as both the primary stimulus for
thrombosis and subsequent thrombus growth on a template
of activated platelets or platelet-derived procoagulant mi-
croparticles (15–17). Our group has shown that patients
with clinically stable coronary artery disease (CAD) have
Table 3. Coagulation Measurements Over Time Among Patients Randomized to Intravenous Heparin Weaning
Baseline 1 h 4 h 24 h
p*Mean SD Mean SD Mean SD Mean SD
Heparin (U/ml) 0.40 0.21 0.21 0.18 0.21 0.23 0.00 0.00 0.11
Factor VII (ng/ml) 615.55 270.62 555.93 232.78 625.10 284.05 631.38 390.26 0.42
Factor VIIa (ng/ml) 2.31 2.31 1.78 1.95 4.02 2.70 3.07 3.37 0.05
TFPI (ng/ml) 115.52 33.77 91.20 27.06 90.63 19.98 78.00 30.59 0.32
TFPI activity (U/ml) 1.15 0.23 1.12 0.29 1.13 0.17 1.09 0.20 0.66
F1.2 (nM) 2.47 1.05 2.43 1.06 2.75 0.76 3.35 0.82 0.04
*p value was from repeated measurements ANOVA for the test of homogeneity for group means. Abbreviations as in Table 2.
Table 2. Coagulation Measurements Over Time Among Patients Randomized to Immediate Discontinuation of Heparin
Baseline 1 h 4 h 24 h
p*Mean SD Mean SD Mean SD Mean SD
Heparin (U/ml) 0.54 0.20 0.41 0.28 0.17 0.11 0.00 0.00 0.005
Factor VII (ng/ml) 574.35 231.38 613.33 184.39 626.83 199.16 612.18 234.22 0.26
Factor VIIa (ng/ml) 1.18 0.62 0.89 0.45 2.45 1.19 1.89 0.96 0.07
TFPI (ng/ml) 132.80 28.04 93.23 31.55 74.73 24.95 86.17 29.30 0.04
TFPI activity (U/ml) 1.32 0.28 1.08 0.18 0.99 0.22 1.14 0.25 0.08
F1.2 (nM) 1.88 0.65 1.85 0.93 2.28 0.94 4.43 1.22 , 0.001
*p value was from repeated measurements ANOVA for the test of homogeneity of group means.
ANOVA 5 analysis of variance; F1.2 5 prothrombin fragment 1.2; TFPI 5 tissue factor pathway inhibitor.
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evidence of increased thrombin activity and generation (18)
as do those with unstable angina (19,20) and acute MI (21)
in whom the abnormality persists for weeks to months after
the presenting event (22). Consistent with prior observa-
tions (23), patients in this study exhibited increased throm-
bin generation despite treatment with UFH (10,18,24,25).
The limitations associated with UFH administration may,
at least in part, be the result of its relative inaccessibility to
clot-bound thrombin and an inability to effectively neutral-
ize factor Xa-mediated procoagulant activity (26).
The thrombogenicity of atheromatous plaques and dys-
functional endothelial cells is strongly influenced by tissue
factor which is considered the predominant “trigger” for
pathologic arterial thrombosis. Accordingly, we focused our
attention on the extrinsic coagulation pathway in general
and factor VII/VIIa-tissue factor in particular (27–31).
Patients with acute coronary syndromes demonstrate high
concentrations of tissue factor antigen and activity within
tissue specimens obtained at the time of coronary atherec-
tomy (32,33), and it has been shown that tissue factor is
released from monocytes after ischemic injury or cellular
death (34). The contribution of tissue factor to intravascular
thrombotic events among individuals with advanced athero-
sclerotic CAD suggests that natural thromboresistance
pathways, particularly TFPI, are of vital importance (35–
38). There is considerable evidence that TFPI contributes to
the antithrombotic effect of heparin. In an original report by
Sandset et al. (39), later confirmed by other investigators
(40–42), TFPI was released from vascular endothelial cells
into the circulation after an IV or SC injection of either
unfractionated or low molecular weight heparin. Tissue
factor pathway inhibitor is bound to endothelial cell surface
glycosaminoglycans; however, the binding is weak and it can
easily be displaced by heparin (43,44). Heparin-releasable
TFPI is not bound to lipoproteins (45) and exerts a strong
anticoagulant effect. Tissue factor pathway inhibitor and
heparin have a synergistic inhibitory effect on tissue factor-
induced coagulation in vitro (46), and it has been suggested
that heparin-mediated TFPI release and mobilization is an
Table 4. Coagulation Measurements Over Time Among Patients Randomized to Subcutaneous Heparin Weaning
Baseline 1 h 4 h 24 h
p*Mean SD Mean SD Mean SD Mean SD
Heparin (U/ml) 0.42 0.22 0.33 0.26 0.18 0.26 0.01 0.01 0.001
Factor VII (ng/ml) 379.61 120.31 419.41 166.04 407.78 103.34 431.26 130.85 0.76
Factor VIIa (ng/ml) 1.49 0.69 1.25 0.67 1.83 0.55 1.94 1.61 0.03
TFPI (ng/ml) 107.35 19.51 96.25 25.16 72.85 18.31 62.13 12.34 0.007
TFPI activity (U/ml) 1.33 0.31 1.31 0.32 1.20 0.31 1.19 0.32 0.09
F1.2 (nM) 2.16 0.71 2.36 0.83 2.36 0.90 3.29 0.87 0.05
*p value was from repeated measurements ANOVA for the test of homogeneity for group means. Abbreviations as in Table 2.
Figure 1. Thrombin generation (F1.2 concentrations) at baseline,
1 h, 4 h and 24 h for the overall patient population and patients
randomized to either immediate discontinuation of heparin (D/C
heparin), intravenous (IV) heparin weaning or subcutaneous (SC)
heparin weaning. Thrombin generation was evident by 1 h and
increased steadily over time. Thrombin generation was greatest
with abrupt heparin cessation and was least with IV heparin
weaning. D/C 5 discontinue; IV 5 intravenous; SC 5 subcuta-
neous.
Figure 2. Factor VIIa concentration over time in the heparin
strategy groups. An increase was observed in all patients; however,
the greatest increase (from baseline) was observed with abrupt
heparin cessation. D/C 5 discontinue; IV 5 intravenous; SC 5
subcutaneous.
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important intrinsic means to limit thrombosis at sites of
vessel wall injury when large quantities of tissue factor are
exposed (41). Depletion of TFPI lowers the threshold for
tissue factor-mediated coagulation (47).
In our study, TFPI declined by 30% to 40% after
modification of the UFH dose with an accompanying rise in
both factor VIIa and thrombin generation, suggesting either
down-regulation or depletion of endothelial cell TFPI,
perhaps in response to prolonged stimulation from a con-
tinuous infusion of UFH. In a study by Hanson et al. (48),
repeated injections of UFH heparin at 4 h intervals caused
a progressive decrease (245 6 8%) in heparin-releasable
TFPI and a progressive shortening of the dilute prothrom-
bin clotting time. During a 24 h continuous infusion of
UFH, TFPI decreased by nearly 80% with a concomitant
decrease in the contribution of TFPI to the inhibition of
tissue factor-mediated coagulation by heparin. The findings
suggest a depletion of intravascular pools of TFPI by
continuous UFH administration and may indicate that the
constitutive synthesis of TFPI is overwhelmed by its elim-
ination under this condition. Potentially compounding the
problem is the common practice and need for IV heparin
bolus doses to exceed a lower threshold of anticoagulation
among patients already receiving a continuous infusion (49).
In our study, patients with acute coronary syndromes were
required to have received a heparin infusion for at least 48 h.
Fifty percent of patients were below the target range at least
once and, according to a standardized weight-adjusted
heparin titration nomogram, received a heparin bolus of 35
to 70 U/kg. Although we did not measure TFPI before
heparin administration, the concentration immediately be-
fore randomization was comparatively low (48) and contin-
ued to decline over time.
We believe that abrupt cessation of UFH provokes a
rapid decrease in TFPI concentration impairing physiologic
vascular thromboresistance and, in the presence of height-
ened factor Xa activity, a sudden burst of thrombin gener-
ation occurs. As long as heparin is present in the circulation,
even in low concentrations, TFPI will not be cleared rapidly.
A proportional decrease in TFPI accompanies a rapid
clearance of heparin (39,50) and normalization of TFPI
toward baseline values parallels heparin elimination. Thus,
there is a declining tissue factor inhibiting capacity that
occurs as the direct anticoagulant effects of heparin are
dissipating. If endothelial cell stores of TFPI are depleted, a
transient prothrombotic state rapidly ensues. Alternatively,
it is possible that activation of the extrinsic coagulation
cascade after tissue factor release from a persistently unsta-
ble atheromatosis plaque (26,35) could consume TFPI in
the process of neutralizing factors VIIa and Xa (36,37). The
provocation of impaired thromboresistance by UFH may
also involve thrombin-thrombomodulin interactions and
protein C activation (51). If this is the case, the suboptimal
inhibition of factors Va, VIIa, VIIIa, Xa and tissue factor
would adversely affect the balance of coagulation (thrombo-
sis) and anticoagulation not only after but during treatment.
Strategies to prevent heparin rebound. Our pilot study
was designed not only to investigate the mechanistic basis
for thrombin generation after UFH cessation but to identify
one or more strategies that could potentially modify the
response and be used routinely in clinical practice. Within
the recent American College of Cardiology (ACC)/
American Heart Association (AHA) Guidelines for the
Management of Patients with Acute MI (52) a concern over
heparin rebound was stated as was the possibility that a
gradual reduction in dose may be preventive. The American
College of Chest Physicians offered support for the SC
weaning strategy (53), whereas the NHLBI-sponsored clin-
ical practice guidelines for unstable angina (1) suggested
that heparin rebound could be prevented by a gradual
discontinuation or SC administration. Neither IV nor SC
UFH weaning has been investigated clinically. The findings
from our randomized pilot study suggest that neither
strategy prevents thrombin generation; however, IV wean-
ing attenuates the response to heparin withdrawal, perhaps
by allowing endothelial cell recovery and restoration of
TFPI-mediated thromboresistance (39,50). The SC wean-
ing strategy achieved a similar result, but the possibility of
delayed rebound was raised by a large proportional increase
in thrombin generation between 4 and 24 h. Although the
SC strategy was designed specifically to slowly lower plasma
heparin concentrations, the level achieved at 4 h was similar
to that observed with sudden heparin cessation. This may
reflect poor or variable SC drug absorption (a recognized
problem with SC UFH administration).
Study limitations. We performed a mechanistic pilot study
to determine biochemical alterations associated with throm-
bin generation after abrupt heparin cessation. Although the
patient population was small and the design was open-label,
Figure 3. Tissue factor pathway inhibitor (TFPI) (total) concen-
tration over time in the heparin strategy groups. There was a
progressive increase in all patients; however, IV heparin weaning
preserved TFPI levels. D/C 5 discontinue; IV 5 intravenous;
SC 5 subcutaneous; TFPI 5 tissue factor pathway inhibitor.
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these factors should not have influenced serial coagulation
measurements. There were two clinical events—both oc-
curred in patients admitted with unstable angina who were
randomized to abrupt UFH cessation. The sample size
prevents firm conclusions from being drawn; however, the
findings are consistent with prior laboratory and clinical
observations and support the proposed mechanism of in-
creased tissue factor-mediated prothrombotic potential.
Conclusions. Although heightened thrombin generation
and a clustering of clinical thrombotic events shortly after
discontinuation of UFH have been recognized previously,
contribution of the extrinsic (tissue factor-mediated) coag-
ulation pathway in general and impairment of TFPI-
mediated vascular thromboresistance in particular have not
been described. An IV weaning strategy offers a means to
attenuate thrombin generation; however, the modest de-
crease may not prevent clinical events.
The findings of our pilot study suggest that future
investigation of strategies to prevent heparin rebound (cur-
rently underway) should focus primarily on tissue factor, the
extrinsic coagulation pathway and anticoagulant therapy-
mediated impairment of physiologic vascular thromboresis-
tance. Potential candidates include low molecular weight
heparin, particularly preparations with a high anti-Xa: IIa
ratio, recombinant TFPI and platelet glycoprotein IIb/IIIa
antagonists that are increasingly being recognized for their
anticoagulant effects mediated by an ability to inhibit tissue
factor-stimulated prothrombinase activity (and thrombin
generation) on platelet aggregates and procoagulant micro-
particles.
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